- Home
- GNRC vs MDGL Comparison
GNRC vs MDGL Comparison
Compare GNRC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- MDGL
- Stock Information
- Founded
- GNRC 1959
- MDGL 2011
- Country
- GNRC United States
- MDGL United States
- Employees
- GNRC N/A
- MDGL N/A
- Industry
- GNRC Metal Fabrications
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- MDGL Health Care
- Exchange
- GNRC Nasdaq
- MDGL Nasdaq
- Market Cap
- GNRC 6.7B
- MDGL 6.8B
- IPO Year
- GNRC 2010
- MDGL N/A
- Fundamental
- Price
- GNRC $121.10
- MDGL $294.64
- Analyst Decision
- GNRC Buy
- MDGL Strong Buy
- Analyst Count
- GNRC 21
- MDGL 10
- Target Price
- GNRC $170.68
- MDGL $420.63
- AVG Volume (30 Days)
- GNRC 794.4K
- MDGL 373.7K
- Earning Date
- GNRC 04-30-2025
- MDGL 05-01-2025
- Dividend Yield
- GNRC N/A
- MDGL N/A
- EPS Growth
- GNRC 58.27
- MDGL N/A
- EPS
- GNRC 5.74
- MDGL N/A
- Revenue
- GNRC $4,348,682,000.00
- MDGL $317,383,000.00
- Revenue This Year
- GNRC $7.27
- MDGL $230.69
- Revenue Next Year
- GNRC $7.29
- MDGL $74.76
- P/E Ratio
- GNRC $21.01
- MDGL N/A
- Revenue Growth
- GNRC 8.07
- MDGL N/A
- 52 Week Low
- GNRC $99.50
- MDGL $200.08
- 52 Week High
- GNRC $195.94
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- GNRC 56.26
- MDGL 39.29
- Support Level
- GNRC $113.50
- MDGL $287.46
- Resistance Level
- GNRC $122.08
- MDGL $349.00
- Average True Range (ATR)
- GNRC 3.81
- MDGL 17.20
- MACD
- GNRC 1.74
- MDGL -2.36
- Stochastic Oscillator
- GNRC 93.36
- MDGL 11.67
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.